Alicia Defay-Stinat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alicia Defay-Stinat has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Benoit Arveiler
University of Bordeaux, Bordeaux, France
2 shared publications - Claudio Plaisant
Service de Génétique Médicale, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
2 shared publications - Daniel John Rigden
Department of Biochemistry, Cell and Systems Biology; Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Crown Street, Liverpool L69 7ZB, United Kingdom
2 shared publications - Eulalie Lasseaux
Service de génétique médicale, centre hospitalier universitaire de Bordeaux, 33076 Bordeaux, France
2 shared publications - Modibo Diallo
Laboratoire Maladies Rares, Génétique et Métabolisme, Bordeaux University, INSERM U1211, 33076 Bordeaux, France
2 shared publications - Shahram Mesdaghi
Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L69 7ZB, UK
2 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 48
OCA2 common variant NM_000275.3:c.574-19A>G affects splicing and is pathogenic.
- 17 June 2026
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 48
Open AccessOCA2 common variant NM_000275.3:c.574-19A>G affects splicing and is pathogenic.
- Open Access
- 8 August 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (16) , 8657
Functional Characterization of Splice Variants in the Diagnosis of Albinism
Albinism is a genetically heterogeneous disease in which 21 genes are known so far. Its inheritance mode is autosomal recessive except for one X-linked form. The molecular analysis of exonic sequences of these genes allows for about a 70% diagnostic rate. About half (15%) of the unsolved cases are heterozygous for one pathogenic or probably pathogenic variant. Assuming that the missing variant may be located in non-coding regions, we performed sequencing for 122 such heterozygous patients of either the whole genome (27 patients) or our NGS panel (95 patients) that includes, in addition to all exons of the 21 genes, the introns and flanking sequences of five genes, TYR, OCA2, SLC45A2, GPR143 and HPS1. Rare variants (MAF < 0.01) in trans to the first variant were tested by RT-PCR and/or minigene assay. Of the 14 variants tested, nine caused either exon skipping or the inclusion of a pseudoexon, allowing for the diagnosis of 11 patients. This represents 9.8% (12/122) supplementary diagnosis for formerly unsolved patients and 75% (12/16) of those in whom the candidate variant was in trans to the first variant. Of note, one missense variant was demonstrated to cause skipping of the exon in which it is located, thus shedding new light on its pathogenic mechanism. Searching for non-coding variants and testing them for an effect on RNA splicing is warranted in order to increase the diagnostic rate.
- 8 August 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (16) , 8657
Open AccessFunctional Characterization of Splice Variants in the Diagnosis of Albinism
Albinism is a genetically heterogeneous disease in which 21 genes are known so far. Its inheritance mode is autosomal recessive except for one X-linked form. The molecular analysis of exonic sequences of these genes allows for about a 70% diagnostic rate. About half (15%) of the unsolved cases are heterozygous for one pathogenic or probably pathogenic variant. Assuming that the missing variant may be located in non-coding regions, we performed sequencing for 122 such heterozygous patients of either the whole genome (27 patients) or our NGS panel (95 patients) that includes, in addition to all exons of the 21 genes, the introns and flanking sequences of five genes, TYR, OCA2, SLC45A2, GPR143 and HPS1. Rare variants (MAF < 0.01) in trans to the first variant were tested by RT-PCR and/or minigene assay. Of the 14 variants tested, nine caused either exon skipping or the inclusion of a pseudoexon, allowing for the diagnosis of 11 patients. This represents 9.8% (12/122) supplementary diagnosis for formerly unsolved patients and 75% (12/16) of those in whom the candidate variant was in trans to the first variant. Of note, one missense variant was demonstrated to cause skipping of the exon in which it is located, thus shedding new light on its pathogenic mechanism. Searching for non-coding variants and testing them for an effect on RNA splicing is warranted in order to increase the diagnostic rate.